Burzynski Research Institute Inc. Quality Score
BZYR
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Negative earnings, no valuation support
Business Quality & Capital Allocation
Roughly flat, no meaningful dilution
Net cash position, no leverage concern
Burzynski Research Institute (BZYR) quality: score, margins and returns
Burzynski Research Institute (BZYR) scores 18/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 2 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Burzynski Research Institute (BZYR) a high-quality business?+
Burzynski Research Institute scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 2 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Burzynski Research Institute's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BZYR's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Burzynski Research Institute scores well and where it falls behind.
SourceQuality score computed from the 10-Q filed 13 Jan 2026, covering the period ending 30 Nov 2025, as reported to the SEC. Data last refreshed 23 Sept 2026. How this is calculated.
Fiscal year ends Feb. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Peers
In Vitro & In Vivo Diagnostic Substances · Pick stocks to compare with BZYR
Spot a number that looks wrong? Check it in BZYR's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BZYR
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.